ANA-ENA, LIA 12 IgG Autoantibody Test at Lahore PCR Lab

ANA-ENA, LIA 12 IgG at Lahore PCR Lab

The ANA-ENA, LIA 12 IgG test is a highly specialized, multiplexed clinical laboratory investigation designed to identify and differentiate specific autoantibodies in patient serum. Autoantibodies are proteins produced by the immune system that mistakenly target the body’s own healthy tissues and cellular components. This comprehensive panel utilizes Line Immunoassay (LIA) technology to simultaneously detect IgG antibodies against 12 distinct Extractable Nuclear Antigens (ENAs) and related nuclear targets. It serves as a crucial diagnostic tool for patients presenting with clinical signs of Systemic Autoimmune Rheumatic Diseases (SARD), also known as connective tissue disorders.

In clinical pathology, the Antinuclear Antibody (ANA) test is typically the initial screening step. When an ANA screen returns positive, or when a patient exhibits strong clinical indications of autoimmune pathology, the ENA LIA panel is performed to identify the exact molecular targets of these autoantibodies. The 12 antigens included in this advanced profile typically encompass dsDNA, Nucleosomes, Histones, Sm, Ribosomal P-protein, nRNP/Sm, SS-A (Ro60), SS-A (Ro52), SS-B (La), Scl-70, PM-Scl, Jo-1, Centromere B, or PCNA, depending on the specific kit configuration. Differentiating these antibodies is of paramount clinical importance because specific autoantibody profiles correlate with distinct clinical diagnoses, disease severity, organ involvement, and overall prognosis.

At Lahore PCR Lab, this test is performed using state-of-the-art automated immunoassay systems. By utilizing purified recombinant and native antigens immobilized as discrete lines on a membrane test strip, the Line Immunoassay provides exceptional specificity and sensitivity. This method minimizes cross-reactivity and delivers clear, semi-quantitative results that assist rheumatologists, immunologists, and internal medicine specialists in formulating accurate treatment strategies. Early and precise identification of these autoantibodies allows for timely therapeutic intervention, which can significantly mitigate systemic organ damage and improve long-term patient outcomes.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the highest level of diagnostic accuracy, patients should observe the following preparation guidelines before undergoing the ANA-ENA, LIA 12 IgG test at Lahore PCR Lab:

• Fasting Requirements: Routine fasting is generally not required for this blood test. Patients may eat and drink normally prior to sample collection. However, if other concurrent blood tests are scheduled (such as a fasting lipid profile or blood glucose test), fasting guidelines for those specific tests must be followed.
• Medication Disclosure: It is critical to inform the laboratory staff and your prescribing physician of all medications you are currently taking. Immunosuppressive therapies, systemic corticosteroids, biologics, and certain disease-modifying antirheumatic drugs (DMARDs) can alter antibody titers and potentially influence test results. Do not discontinue any prescribed medication without consulting your physician.
• Hydration: Staying well-hydrated by drinking adequate amounts of water is highly recommended. Proper hydration facilitates easier venous access and a smoother blood draw experience.
• Timing: The test can be performed at any time during the laboratory’s operational hours, as diurnal variations do not significantly impact IgG autoantibody levels.

During the Procedure

The ANA-ENA, LIA 12 IgG test requires a standard peripheral blood draw (venipuncture). The procedure is conducted by highly trained phlebotomists at Lahore PCR Lab and involves the following steps:

• Patient Identification and Verification: The phlebotomist will verify your identity using your registration details and confirm the requested test panel.
• Site Selection and Preparation: You will be seated comfortably. The phlebotomist will inspect your arm to locate a suitable vein, typically in the antecubital fossa (the bend of the elbow). The selected site is thoroughly cleansed with an antiseptic solution (such as isopropyl alcohol) and allowed to air dry to prevent sample contamination and infection.
• Venipuncture: A sterile, single-use needle attached to a vacuum collection tube (typically a Serum Separator Tube, or SST with a gold/red top) is gently inserted into the vein. You may feel a brief, mild pinch or stinging sensation as the needle enters.
• Sample Collection: The required volume of blood (usually 3 to 5 milliliters) is drawn into the tube. Once the collection is complete, the tourniquet is released, and the needle is carefully withdrawn.
• Post-Draw Care: Immediate pressure is applied to the puncture site using a sterile gauze pad or cotton ball to promote hemostasis and prevent hematoma formation. A small adhesive bandage is then applied. The entire collection process takes less than five minutes.
• Laboratory Processing: The collected blood sample is allowed to clot completely at room temperature before undergoing centrifugation. Centrifugation separates the liquid serum from the cellular components. The isolated serum is then processed using the Line Immunoassay (LIA) platform, where it is incubated with the antigen-coated strips to detect specific IgG autoantibodies.

When is an ANA-ENA, LIA 12 IgG Test Performed?

Systemic Lupus Erythematosus (SLE) Suspected

Physicians request this comprehensive panel when a patient exhibits symptoms suggestive of Systemic Lupus Erythematosus (SLE). Key clinical presentations include a characteristic malar (butterfly) rash across the cheeks and bridge of the nose, photosensitivity, unexplained chronic fever, joint pain with swelling, and persistent fatigue. Identifying specific antibodies such as anti-dsDNA, anti-Sm, and anti-ribosomal P-protein within the LIA 12 panel helps confirm an SLE diagnosis, assess the risk of lupus nephritis, and monitor disease activity.

Sjögren’s Syndrome Evaluation

This test is highly indicated for patients presenting with severe, chronic dryness of the eyes (keratoconjunctivitis sicca) and mouth (xerostomia), which are hallmark symptoms of Sjögren’s Syndrome. This autoimmune condition targets the exocrine glands. The LIA 12 panel evaluates the presence of anti-SS-A (Ro) and anti-SS-B (La) antibodies. Detecting these specific markers is crucial for differentiating primary Sjögren’s Syndrome from secondary forms associated with other connective tissue diseases.

Systemic Sclerosis (Scleroderma) Diagnosis

When patients present with skin thickening, tightening (particularly of the fingers and face), Raynaud’s phenomenon (exaggerated cold sensitivity causing color changes in the fingers), or esophageal dysfunction, systemic sclerosis is suspected. The ANA-ENA LIA panel assists in diagnosing this complex condition by detecting anti-Scl-70 (topoisomerase I) and anti-Centromere B antibodies. These markers help clinicians distinguish between diffuse cutaneous systemic sclerosis and limited cutaneous systemic sclerosis (CREST syndrome).

Mixed Connective Tissue Disease (MCTD) Investigation

Mixed Connective Tissue Disease is an overlap syndrome characterized by clinical features shared among SLE, systemic sclerosis, and polymyositis. Patients often present with swollen hands, Raynaud’s phenomenon, joint inflammation, and muscle weakness. The presence of exceptionally high titers of anti-U1-RNP (specifically the 70 kDa, A, or C proteins) in the absence of other SARD-specific antibodies is the diagnostic cornerstone for MCTD, which is easily evaluated via the LIA 12 panel.

Inflammatory Myopathies (Polymyositis/Dermatomyositis)

Physicians order this panel when patients exhibit progressive, symmetrical muscle weakness, particularly in the proximal muscles (shoulders and hips), sometimes accompanied by distinct skin lesions such as Gottron’s papules or a heliotrope rash. The inclusion of the anti-Jo-1 antibody in the LIA 12 panel is vital, as it is a highly specific marker for polymyositis and dermatomyositis, and is strongly associated with antisynthetase syndrome, which includes interstitial lung disease.

What Does an ANA-ENA, LIA 12 IgG Test Detect?

The ANA-ENA, LIA 12 IgG panel is designed to detect a spectrum of autoantibodies, each pointing to specific pathological processes and clinical conditions. The assay evaluates IgG antibodies directed against the following key antigens:

• Anti-dsDNA: Highly specific for Systemic Lupus Erythematosus (SLE). Levels often correlate with disease activity and the development of lupus nephritis.
• Anti-Nucleosome: An important marker for SLE, particularly in patients who are negative for anti-dsDNA. It plays a significant role in the pathogenesis of lupus-associated renal damage.
• Anti-Histone: Strongly associated with Drug-Induced Lupus Erythematosus (DILE), though also found in idiopathic SLE.
• Anti-Sm (Smith): Considered pathognomonic (highly specific) for SLE. Its presence is a key criterion in international classification guidelines for lupus.
• Anti-U1-RNP (nRNP/Sm): The diagnostic marker for Mixed Connective Tissue Disease (MCTD) when present in high titers. It can also be detected in SLE.
• Anti-SS-A / Ro60: Commonly associated with Sjögren’s Syndrome and SLE. It is also linked to subacute cutaneous lupus and neonatal lupus.
• Anti-SS-A / Ro52: Often found in association with Ro60, but can occur independently in various autoimmune diseases, including inflammatory myopathies and systemic sclerosis. It is clinically significant in congenital heart block risk assessment.
• Anti-SS-B / La: Frequently co-exists with anti-SS-A in patients with Sjögren’s Syndrome and SLE. Its presence reduces the likelihood of lupus nephritis.
• Anti-Scl-70 (Topoisomerase I): Highly specific for diffuse cutaneous systemic sclerosis. It is a strong predictor of pulmonary fibrosis and severe systemic involvement.
• Anti-PM-Scl: Associated with PM/Scl overlap syndrome, combining features of polymyositis and systemic sclerosis.
• Anti-Jo-1 (Histidyl-tRNA Synthetase): The primary marker for antisynthetase syndrome, characterized by myositis, interstitial lung disease, arthritis, and Raynaud’s phenomenon.
• Anti-Centromere B: Strongly associated with limited cutaneous systemic sclerosis (CREST syndrome) and carries a lower risk of severe pulmonary fibrosis compared to Scl-70.

Turnaround Time and Report Access at Lahore PCR Lab

At Lahore PCR Lab, we understand the anxiety and clinical urgency associated with diagnostic testing for autoimmune diseases. We utilize advanced, high-throughput Line Immunoassay systems to ensure both rapid processing and clinical precision. The typical turnaround time for the ANA-ENA, LIA 12 IgG panel is 24 to 48 hours from the time of sample collection.

Once the analysis is complete, the results undergo a rigorous multi-stage validation process by our consultant clinical pathologists to ensure absolute accuracy. Patients and referring physicians are immediately notified via SMS when the report is ready. Reports can be accessed securely online through the Lahore PCR Lab web portal, downloaded via WhatsApp, or collected in person from our main diagnostic center. This seamless digital reporting system ensures that your healthcare provider can review the findings promptly and initiate appropriate clinical management without delay.

ANA-ENA, LIA 12 IgG Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Anti-dsDNA IgG	Negative / Non-reactive	Positive (Highly suggestive of SLE; monitors renal risk)
Anti-Sm IgG	Negative / Non-reactive	Positive (Highly specific diagnostic marker for SLE)
Anti-U1-RNP IgG	Negative / Non-reactive	Positive (High titers indicate Mixed Connective Tissue Disease)
Anti-SS-A (Ro60/Ro52) IgG	Negative / Non-reactive	Positive (Sjögren’s Syndrome, SLE, neonatal lupus risk)
Anti-SS-B (La) IgG	Negative / Non-reactive	Positive (Sjögren’s Syndrome, SLE overlap)
Anti-Scl-70 IgG	Negative / Non-reactive	Positive (Diffuse Systemic Sclerosis; risk of pulmonary fibrosis)
Anti-Centromere B IgG	Negative / Non-reactive	Positive (Limited Systemic Sclerosis / CREST Syndrome)
Anti-Jo-1 IgG	Negative / Non-reactive	Positive (Polymyositis, Dermatomyositis, Antisynthetase Syndrome)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for ANA-ENA, LIA 12 IgG?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly qualified pathologists, immunologists, and medical technologists specializing in autoimmune diagnostics.
• Patient-Focused Care: We prioritize patient comfort, safety, and clear communication throughout the testing process.
• Quality Diagnostic Services: Lahore PCR Lab adheres to strict internal and external quality control protocols to deliver highly reproducible and precise results.
• Professional Reporting: Our detailed reports provide clear, semi-quantitative values for all 12 parameters, making interpretation straightforward for clinicians.
• Modern Diagnostic Approach: We utilize advanced Line Immunoassay (LIA) technology, which offers superior specificity compared to older screening methods.
• Comfortable Environment: Our diagnostic centers in Lahore are designed to provide a clean, hygienic, and stress-free environment for blood sample collection.
• Convenient Location: Easily accessible locations across Lahore ensure that patients can access our diagnostic services without long commutes.
• Commitment to Accurate Diagnosis: We understand the critical role of diagnostic accuracy in managing complex autoimmune diseases and are dedicated to supporting your healthcare journey.